Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
ONC received a notice of proposed sale of up to 49,541 ADS to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services on 07/10/2026, with an aggregate market value of $15,002,501.03. The issuer reports 54,885,669 ADS outstanding. The filing also lists recent common share sales by John V. Oyler in June 2026, including 4,940 shares for $1,336,566.40 on June 8 and several smaller transactions later in the month.
BeOne Medicines Ltd. reports the conclusion of a statutory tax audit in China that resulted in a settlement requiring an income tax payment of approximately RMB 446 million, including surcharges and related interest. The payment stems from agreed adjustments to previously filed tax returns and involves no administrative penalty.
The company indicates this income tax payment will be recognized in its U.S. GAAP financial statements for the second quarter of fiscal 2026. The disclosure follows earlier discussion of ongoing international tax audits that may lead to outcomes different from prior estimates because of complex local tax rules.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported a small share disposal tied to tax withholding rather than a discretionary sale. On June 23, 2026, 1,292 American Depositary Shares (ADS) were sold at a weighted average price of $276.2592 per ADS under a mandatory tax withholding provision associated with the vesting of a restricted share unit award.
The restricted share units vest in four equal installments on each anniversary of June 22, 2022, subject to continued service, with potential accelerated vesting upon certain termination events. Following this transaction, Wu holds 12,365 ADS directly, 4,000 ADS indirectly through his spouse, and 1,273,724 ordinary shares directly.
BeOne Medicines Ltd. director and CEO John Oyler reported transactions involving American Depositary Shares (ADSs) tied to his equity compensation. On June 23, 2026, entities associated with him disposed of a total of 3,410 ADSs in open-market sales at weighted average prices between $272.655 and $275.21.
Each ADS represents 13 Ordinary Shares. Footnotes state these sales were effected under a mandatory tax withholding provision in his restricted share unit award agreement upon vesting, rather than as discretionary sales. Following these transactions, Oyler holds 5,605,310 Ordinary Shares directly and additional Ordinary Shares indirectly through various trusts and an LLC, while he disclaims beneficial ownership of certain trust-held securities.
BeOne Medicines Ltd. President and Global Head of R&D Wang Lai reported a small sale of 1,068 American Depositary Shares of the company. The shares were sold at $276.735 per ADS and the transaction is described as an open-market sale.
According to a footnote, this sale was carried out under a mandatory tax withholding provision tied to the vesting of a restricted share unit award that began vesting on June 22, 2022. Each ADS represents 13 ordinary shares.
After these transactions, Wang Lai holds 1,681,004 ordinary shares directly and 601,965 ordinary shares indirectly. Additional RMB Shares are held through structures such as Wang Holdings LLC and an RMB Shares Employee Participation Plan, where he has only indirect economic interest and explicitly disclaims Section 16 beneficial ownership beyond any pecuniary interest.
ONC affiliate files a Form 144 proposing the sale of 1,068 ADS. The filing states the ADS are related to Restricted Stock Vesting Under a Registered Plan and identifies Morgan Stanley Smith Barney LLC as the broker. The excerpt also lists recent ADS sales by Lai Wang: 1,169 ADS on 06/16/2026 (310,235.88), 756 ADS on 06/11/2026 (197,629.74), and 1,367 ADS on 06/08/2026 (368,246.83).
XIAOBIN WU reported sales of ADS (American Depositary Shares). The filing lists three ADS dispositions: 1,357 ADS for $361,996.85 on 06/16/2026, 626 ADS for $163,512.26 on 06/11/2026, and 1,484 ADS for $399,738.11 on 06/08/2026. The form also lists a separate ADS entry of 1,292 ADS tied to Restricted Stock Vesting Under a Registered Plan dated 06/22/2026.
ONC files a Form 144 to sell 3,410 ADS. The filing lists the sale as Restricted Stock Vesting Under a Registered Plan, with the issuer identified as the recipient of the vested ADS on 06/22/2026. The excerpt also reports three recent ADS dispositions by John Oyler: 4,940 ADS on 06/08/2026, 1,949 ADS on 06/11/2026, and 3,693 ADS on 06/16/2026, each showing corresponding gross proceeds.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported an open-market sale of 1,357 American Depositary Shares (ADS) at a weighted average price of $266.7626 per ADS. The footnotes state this sale was mandated by a tax withholding provision tied to the vesting of a restricted share unit (RSU) award previously granted to him.
Each ADS represents 13 ordinary shares. Following the transaction, Wu holds 12,365 ADS directly, 4,000 ADS indirectly through his wife, and 1,290,520 ordinary shares directly, indicating he retains a substantial equity position. The RSU award vests in four equal annual installments on each anniversary of June 15, 2023, with unvested units subject to accelerated vesting upon certain termination events.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported open‑market sales of 3,693 American Depositary Shares on June 16, 2026. The ADS were sold in three trades at weighted average prices of about $264.87 to $266.69 per ADS.
According to a footnote, these sales were executed under a mandatory tax‑withholding provision tied to the vesting of a restricted share unit award previously granted to him. After these transactions, Oyler directly holds 5,649,640 Ordinary Shares and also reports several indirect Ordinary Share holdings via trusts and an LLC, for some of which he disclaims beneficial ownership.